Drug Insights

Unveiling Metformin: How to Search for it on Synapse

2 February 2024
2 min read

Metformin Hydrochloride, sold under the trade name GLUCOPHAGE, is a medication used in the treatment of type 2 diabetes mellitus. It was first approved in France in 1957 and is now manufactured by Bristol Myers Squibb Co. GLUCOPHAGE works by activating PRKAB1, which helps to improve glycemic control in both adult and pediatric patients aged 10 years and older, when used in combination with diet and exercise. This medication is a biguanide, and it is commonly used as an adjunct therapy to help manage blood sugar levels in individuals with type 2 diabetes. Click on the image below to begin the exploration journey of Metformin through the Synapse database!

图形用户界面, 应用程序

描述已自动生成

You can search for the latest pharmaceutical information such as drugs, targets, patents, transactions, clinical results, etc. through the Synapse database. Come and experience it!

图形用户界面, 文本, 应用程序, 聊天或短信

描述已自动生成

Expert Tips for Searching Ondansetron on Synapse
Drug Insights
2 min read
Expert Tips for Searching Ondansetron on Synapse
2 February 2024
ZOFRAN® (Ondansetron Hydrochloride) is a medication used to prevent nausea and vomiting associated with emetogenic cancer chemotherapy and postoperative nausea and/or vomiting.
Read →
Navigating Health Information: How to Use Synapse to Search for Losartan
Drug Insights
2 min read
Navigating Health Information: How to Use Synapse to Search for Losartan
2 February 2024
Cozaar® (losartan potassium) is a drug for treating hypertension, left ventricular hypertrophy, and type 2 diabetes-related nephropathy.
Read →
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Melatonin
Drug Insights
2 min read
Optimize Your Synapse Experience: A Step-by-Step Guide to Searching Melatonin
1 February 2024
Melatonin is a small molecule drug that acts on melatonin receptors, functioning as an agonist.
Read →
CBR-701 (SYS6002): A Novel Nectin-4-Targeted Therapy Showing Promise in Initial Human Trials for Cancer Patients
Latest Hotspot
3 min read
CBR-701 (SYS6002): A Novel Nectin-4-Targeted Therapy Showing Promise in Initial Human Trials for Cancer Patients
1 February 2024
CBR-701 (SYS6002), a cutting-edge therapeutic agent aimed at Nectin-4, exhibits promising outcomes in initial human trials with Nectin-4 positive cancer patients.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.